Profile

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of February 2014, Repligen employed 116 people, about 50% of these based in Sweden. Prior to 2012, Repligen maintained dual capabilities in the development of pharmaceutical therapeutics and the development of materials supporting biological drug manufacture . A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures. In the period of 2010 to 2013, the majority of sales by the company were concentrated in the single Protein A product line.